We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

159 hedge funds and large institutions have $612M invested in Progenics Pharmaceuticals Inc in 2017 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 16

69% more call options, than puts

Call options by funds: $6.1M | Put options by funds: $3.62M

26% more funds holding

Funds holding: 126 → 159 (+33)

25% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 36

18% more capital invested

Capital invested by funds: $518M → $612M (+$93.5M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
159
Holders Change
+33
Holders Change %
+26.19%
% of All Funds
3.96%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
56
Increased
45
Reduced
36
Closed
16
Calls
$6.1M
Puts
$3.62M
Net Calls
+$2.48M
Net Calls Change
+$1.34M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$95M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$13M
3
PWAM
Park West Asset Management
California
+$12.6M
4
Invesco
Invesco
Georgia
+$10.3M
5
Goldman Sachs
Goldman Sachs
New York
+$5.62M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$69.4M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.91M
3
AllianceBernstein
AllianceBernstein
Tennessee
-$2.13M
4
RA
Royce & Associates
New York
-$2.08M
5
PFC
Phocas Financial Corp
California
-$1.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
MA
151
MUFG Americas
New York
$2K – – –
AIM
152
Advantage Investment Management
Iowa
$1K – – –
HMS
153
Hanseatic Management Services
New Mexico
$1K – – –
TWA
154
TCI Wealth Advisors
Arizona
$1K +$529 +53 New
PHK
155
Point72 Hong Kong
Hong Kong
$1K +$779 +78 New
Walleye Trading
156
Walleye Trading
New York
$17 -$61.9K -6,200 -78%
TC
157
TFS Capital
Pennsylvania
– -$1.51M -174,408 Closed
BIM
158
Bogle Investment Management
Massachusetts
– -$993K -115,008 Closed
TI
159
Turner Investments
Pennsylvania
– -$946K -109,436 Closed
CCMH
160
Cornerstone Capital Management Holdings
New York
– -$289K -33,500 Closed
SEI Investments
161
SEI Investments
Pennsylvania
– -$276K -31,900 Closed
SG Americas Securities
162
SG Americas Securities
New York
– -$233K -26,951 Closed
GCP
163
GSA Capital Partners
United Kingdom
– -$163K -18,890 Closed
DTL
164
Dynamic Technology Lab
Singapore
– -$144K -16,596 Closed
PP
165
Paloma Partners
Connecticut
– -$121K -13,992 Closed
EMG
166
Ellington Management Group
Connecticut
– -$112K -13,000 Closed
HSBC Holdings
167
HSBC Holdings
United Kingdom
– -$112K -12,940 Closed
Group One Trading
168
Group One Trading
Illinois
– -$124K -12,390 Closed
RFCA
169
R&F Capital Advisors
New York
– -$96K -11,119 Closed
FM
170
Family Management
New York
– -$86K -10,000 Closed
Simplex Trading
171
Simplex Trading
Illinois
– -$5.16K -517 Closed
PRS
172
Pinkerton Retirement Specialists
Idaho
– -$1K -80 Closed
MSFP
173
Mark Sheptoff Financial Planning
Connecticut
– +$10 +1 +10%
PFBT
174
Parkside Financial Bank & Trust
Missouri
– +$309 +31 New
Carson Wealth (CWM LLC)
175
Carson Wealth (CWM LLC)
Nebraska
– +$329 +33 New
3 4 5 6
7

PGNX Hedge Fund Activity: Q1 2017 in Review

159 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q1 2017, worth a combined $612M — up 18% from $518M a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new PGNX positions and 16 closed out — a net gain of 40 holders — while 45 added to existing stakes and 36 trimmed.

The largest buyer was BlackRock, adding an estimated $95M. The largest seller was Broadfin Capital, cutting an estimated $69.4M.

  • 159 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q1 2017, up from 126 in Q4 2016.
  • Funds reported $612M of Progenics Pharmaceuticals Inc stock for Q1 2017, up 18% quarter-over-quarter.
  • 56 funds opened new Progenics Pharmaceuticals Inc positions in Q1 2017 and 16 closed out, a net change of +40 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q1 2017 was BlackRock, an estimated $95M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q1 2017 was Broadfin Capital, an estimated $69.4M sold.

Based on aggregated 13F filings for Q1 2017.